A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/22/2011	US20110312924 Novel steroidal cyp17 inhibitors/antiandrogens
12/22/2011	US20110312922 EDTA Resistant S100A12 Complexes (ERAC)
12/22/2011	US20110312921 N-Myristoyl Transferase Inhibitors
12/22/2011	US20110312919 Inhibitors of tyrosine kinase receptor dimerization
12/22/2011	US20110312918 Method for identifying agents for inhibiting cell motility and invasiveness
12/22/2011	US20110312916 Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
12/22/2011	US20110312909 Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent
12/22/2011	US20110312908 Small molecule myristate inhibitors of bcr-abl and methods of use
12/22/2011	US20110312905 Stimulus-triggered prodrugs
12/22/2011	US20110312904 Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
12/22/2011	US20110312899 HDL Particles for Delivery of Nucleic Acids
12/22/2011	US20110312898 Prophylactic / therapeutic agent for cancer
12/22/2011	US20110312897 Cathepsin l proteolytically processes histone h3 during mouse embryonic stem cell differentiation
12/22/2011	US20110312896 Inhibitors of bcl-2
12/22/2011	US20110312879 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
12/22/2011	US20110312878 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/22/2011	US20110312873 N-terminally modified tetrapeptide derivatives having a c-terminal arginine mimetic
12/22/2011	US20110312872 Norrin in the treatment of diseases associated with an increased tgf-beta activity
12/22/2011	US20110311652 Novel Saponin Compounds, Methods of Preparation Thereof, Use Thereof and Pharmaceutical Compositions
12/22/2011	US20110311651 Cardenolides for the treatment of ocular cancer
12/22/2011	US20110311648 Novel Methods for the Treatment of Cancer
12/22/2011	US20110311624 Formulations of histone deacetylase inhibitor and uses thereof
12/22/2011	US20110311616 Targeting tumor associated macrophages using bisphosphonate-loaded particles
12/22/2011	US20110311613 Topical formulations of flap inhibitors for the treatment of dermatological conditions
12/22/2011	US20110311592 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
12/22/2011	US20110311584 Use of flt3 ligand for enhancing immune responses in rna immunization
12/22/2011	US20110311582 Novel lipids and compositions for the delivery of therapeutics
12/22/2011	US20110311564 Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles
12/22/2011	US20110311561 Non-natural mic proteins
12/22/2011	US20110311557 Reciprocal serum/plasma exchange for the treatment of cancer
12/22/2011	US20110311555 Tc11 as a Transcriptional Regulator
12/22/2011	US20110311552 Notch1 receptor binding agents and methods of use thereof
12/22/2011	US20110311546 Angiopoietin-2 specific binding agents
12/22/2011	US20110311544 Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells
12/22/2011	US20110311543 Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer
12/22/2011	US20110311541 Mutant proteins of the f protein of piv-5 and piv-2
12/22/2011	US20110311540 Wisp polypeptides and nucleic acids encoding same
12/22/2011	US20110311539 Diagnosis and treatment of cancer using cancer-testis antigens
12/22/2011	US20110311538 Inhibitors of receptor tyrosine kinases and methods of use thereof
12/22/2011	US20110311535 Nkg2d-fc for immunotherapy
12/22/2011	US20110311534 Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
12/22/2011	US20110311532 Inhibition of complement and cellular activation
12/22/2011	US20110311531 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/22/2011	US20110311530 Truncated baff receptors
12/22/2011	US20110311525 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
12/22/2011	US20110311524 Inhibitors of Angiopoietin-Like 4 Protein, Combinations, and Their Use
12/22/2011	US20110311517 Antibodies and methods for treating estrogen receptor-associated diseases
12/22/2011	US20110311516 Chemically Programmed Vaccination
12/22/2011	US20110311508 Method of modulating hsf-1
12/22/2011	US20110311505 Photosensitive Aminoacid-Monomer Linkage and Bioconjugation Applications in Life Sciences and Biotechnology
12/22/2011	US20110311500 Combination bacteriolytic therapy for the treatment of tumors
12/22/2011	US20110311485 1,2,4-oxadiazole derivatives and their therapeutic use
12/22/2011	US20110311483 Crth2 modulators
12/22/2011	US20110311481 Methods and Compositions for Contributing to the Treatment of Cancers
12/22/2011	US20110311479 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
12/22/2011	US20110311478 Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
12/22/2011	US20110311477 Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies
12/22/2011	US20110311476 Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation
12/22/2011	US20110311474 Novel Tricyclic Compounds
12/22/2011	US20110311472 Application of mrna for use as a therapeutic against tumour diseases
12/22/2011	US20110311452 Inflammation targeting particles
12/22/2011	US20110311451 Synthesis of polymer conjugates of indolocarbazole compounds
12/22/2011	US20110311450 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
12/22/2011	US20110311449 Antibodies
12/22/2011	US20110311446 Peptides that specifically bind hgf receptor (cmet) and uses thereof
12/22/2011	US20110311445 Diagnosis and treatment of myeloid and lymphoid cell cancers
12/22/2011	US20110311443 Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
12/22/2011	DE102010034595A1 Use of an active ingredient of a histone demethylase inhibitor for treating cancer/tumors and/or neoplastic diseases, where the histone demethylase is from Jumonji/AT-rich interactive domain-containing protein family
12/22/2011	CA2838694A1 Lung regeneration using cord blood-derived hematopoietic stem cells
12/22/2011	CA2805406A1 Growth hormone secretatogue receptor antagonists and uses thereof
12/22/2011	CA2802974A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
12/22/2011	CA2802761A1 Methods of treating or preventing estrogen-related diseases
12/22/2011	CA2802631A1 S100a4 antibodies and therapeutic uses thereof
12/22/2011	CA2802629A1 Substituted triazolopyridines
12/22/2011	CA2802388A1 Compositions and methods for treating cancer
12/22/2011	CA2802376A1 Anti-vegf antibodies and uses thereof
12/22/2011	CA2802349A1 Anti-dr4 agonist antibodies
12/22/2011	CA2802344A1 Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
12/22/2011	CA2801210A1 Anti-gd2 antibodies
12/22/2011	CA2794731A1 Anti-axl antibodies and methods of use
12/21/2011	EP2397494A1 Human antibodies that bind human TNFalpha
12/21/2011	EP2397481A1 Inhibitor of casein kinase 1delta and casein kinase 1epsilon
12/21/2011	EP2397479A1 Hetero ring derivative
12/21/2011	EP2397478A1 1,3-diaryl substituted ureas as modulators of kinase activity.
12/21/2011	EP2397469A1 Diarylhydantoin compounds
12/21/2011	EP2397157A1 Brain tumor stem cell differentiation promoter, and therapeutic agent for brain tumor
12/21/2011	EP2397149A1 Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p)
12/21/2011	EP2397146A1 Parvovirus for treatment of tumours by intranasal application
12/21/2011	EP2397138A1 Method of inhibiting C-KIT kinase
12/21/2011	EP2396407A1 C-cbl and antagonists thereof for the treatment and diagnosis of cancer
12/21/2011	EP2396333A1 Triazolo [4,3-b]pyridazine derivatives and their uses for prostate cancer
12/21/2011	EP2396331A1 Fused pyrimidines as akt inhibitors
12/21/2011	EP2396330A1 Fused pyrimidines
12/21/2011	EP2396326A1 Spiroindolinone pyridine derivative
12/21/2011	EP2396325A1 Derivatives of azaindoles as inhibitors of protein kinases abl and src
12/21/2011	EP2396313A1 Isotopologues of thalidomide
12/21/2011	EP2396312A1 Isotopologues of lenalidomide
12/21/2011	EP2396311A2 Solid pharmaceutical composition comprising the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate and polymorphs thereof
12/21/2011	EP2396307A1 Novel amino azaheterocyclic carboxamides
12/21/2011	EP2396297A1 Androgen receptor modulating compounds, preparation and uses thereof

1 ... 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 ... 2211